Valuation: Virbac

Market Cap 2.87B 3.27B 2.64B 2.47B 4.64B 308B 4.73B 31.74B 12.28B 152B 12.27B 12B 528B P/E 2026 *
17x
P/E 2027 * 15.2x
Enterprise Value 2.99B 3.41B 2.75B 2.58B 4.83B 321B 4.93B 33.08B 12.8B 159B 12.79B 12.51B 551B EV / Sales 2026 *
1.93x
EV / Sales 2027 * 1.76x
Free-Float
49.03%
Yield 2026 *
0.51%
Yield 2027 * 0.6%
1 week+0.44%
Current month-4.62%
1 month-6.33%
3 months-3.95%
6 months-2.44%
Current year-4.22%
1 week 332.5
Extreme 332.5
344.5
1 month 327.5
Extreme 327.5
369.5
3 years 241
Extreme 241
394.5
5 years 216.5
Extreme 216.5
441.5
10 years 101.68
Extreme 101.682
441.5
Manager TitleAgeSince
Chief Executive Officer 46 2025-08-31
Chief Executive Officer 50 2024-09-26
Chief Operating Officer 64 2021-12-31
Director TitleAgeSince
Chairman 61 2006-03-31
Director/Board Member 68 2010-07-27
Director/Board Member 65 2017-09-04
Change 5-day change 1-year change 3-year change Capi.($)
-0.15%+0.44%+8.44%+28.73% 3.27B
-2.22%-3.33%-51.16%-54.58% 31.9B
+0.82%+1.45%+71.82%+148.68% 12.27B
-2.32%-7.83%-8.31%+13.79% 4B
-5.30%-2.80%+46.48%+25.44% 1.84B
-2.32%-0.51%-25.06%-4.07% 1.6B
-0.44%-0.50%+26.15%+137.38% 1.29B
-2.97%-5.39%-24.47%-18.80% 960M
+0.70%+4.47%-0.82%-16.78% 960M
-1.33%-6.60%-17.27%-48.44% 892M
Average -1.71%-2.33%+2.58%+21.13% 6.19B
Weighted average by Cap. -1.57%-2.40%-12.16%+6.31%

Financials

2026 *2027 *
Net sales 1.55B 1.76B 1.43B 1.33B 2.5B 166B 2.55B 17.13B 6.63B 82.22B 6.62B 6.48B 285B 1.64B 1.87B 1.51B 1.41B 2.65B 176B 2.71B 18.16B 7.03B 87.18B 7.02B 6.87B 302B
Net income 167M 190M 154M 144M 270M 17.97B 276M 1.85B 716M 8.88B 715M 700M 30.8B 190M 217M 175M 164M 308M 20.46B 314M 2.11B 815M 10.11B 815M 797M 35.07B
Net Debt 121M 138M 112M 104M 196M 13.02B 200M 1.34B 519M 6.43B 518M 507M 22.31B 26.49M 30.21M 24.42M 22.86M 42.87M 2.85B 43.76M 294M 114M 1.41B 113M 111M 4.88B
Logo Virbac
Virbac specializes in the research, production and marketing of veterinary medicines. Net sales break down by family of products as follows: - pet medications (60.7%): pest control drugs, vaccines, antibiotics, anesthetics, anti-inflammatory drugs, mouth/dental care products, ophthalmologic and dermatological products intended for dogs, cats, horses, birds, rodents, etc. The group also offers foods and electronic identification chips; - livestock medications (39.3%): pest control drugs and antibiotics intended for cattle, sheep, pigs, poultry, etc. Net sales are distributed geographically as follows: Europe (41.6%), Latin America (15.2%), North America (13.6%), India/Africa/Middle East (12.2%), Eastern Asia (10.5%) and Pacific (6.9%).
Employees
-
Date Price Change
26-06-26 €340.50 -0.15%
26-06-25 €341.00 +0.74%
26-06-24 €338.50 +1.20%
26-06-23 €334.50 -0.74%
26-06-22 €337.00 -0.59%
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
342.00EUR
Average target price
412.88EUR
Spread / Average Target
+20.72%

Quarterly revenue - Rate of surprise